



Haleon plc: Director/PDMR Shareholding

19 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Adrian Morris					
2	Reason for the notification						
a)	Position/status	General Counsel - PDMR					
b)	Initial notification /Amendment	Initial Notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Haleon plc					
b)	LEI	549300PSB3WWEODCUP19					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each					
	Identification code	GB00BMX86B70					
b)	Nature of the transaction	Grant of a 3-year option over Ordinary Shares under the 2024 Haleon Share Save Plan which will first become exercisable 1 February 2028.					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£3.00</td><td>6,150</td></tr></table>		Price(s)	Volume(s)	£3.00	6,150
Price(s)	Volume(s)						
£3.00	6,150						
d)	Aggregated information - Aggregated volume - Price						
e)	Date of the transaction	19 December 2024					
f)	Place of the transaction	Outside a trading venue					

Amanda Mellor
Company Secretary

About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better

everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBSBDDXUBDGSC